Reviewing Lunai Bioworks (NASDAQ:LNAI) and Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions (NYSE:EBS) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Emergent Biosolutions and Lunai Bioworks”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90 million	0.40	$52.60 million	($5.10)	-1.14
Lunai Bioworks	$51,992.00	15.96	-$3.56 million	($0.40)	-0.41

Emergent Biosolutions has higher revenue and earnings than Lunai Bioworks. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Emergent Biosolutions has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Emergent Biosolutions and Lunai Bioworks, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2	1	3	0	2.17
Lunai Bioworks	1	0	0	0	1.00

Emergent Biosolutions currently has a consensus price target of $10.00, indicating a potential upside of 71.97%. Given Emergent Biosolutions’ stronger consensus rating and higher probable upside, research analysts plainly believe Emergent Biosolutions is more favorable than Lunai Bioworks.

Institutional & Insider Ownership

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Emergent Biosolutions and Lunai Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-40.16%	-0.43%	-0.15%
Lunai Bioworks	N/A	N/A	-42.62%

Summary

Emergent Biosolutions beats Lunai Bioworks on 9 of the 14 factors compared between the two stocks.

About Emergent Biosolutions

Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.